Daily Roundup

GYG.ASX ENL.ASX CU6.ASX XRG.ASX RAC.ASX

Clarity Pharmaceuticals Advances Copper-64 Capabilities and Promising Prostate Cancer Trials

Clarity Pharmaceuticals has been busy on multiple fronts. The company has signed a new agreement with the University of Queensland (UQ) for the supply of copper-64 isotope to support its clinical trials and pre-clinical programs. This enhances Clarity's ongoing collaborations with UQ, including research and development initiatives.

In other news, Clarity provided an update on its SECuRE trial for the 67Cu-SAR-bisPSMA product. The trial has progressed to the Cohort Expansion Phase (Phase II) after demonstrating favorable safety and efficacy data in the Dose Escalation Phase. Notably, 92% of pre-chemotherapy participants experienced a >35% drop in PSA levels. The trial protocol has been amended to bring 67Cu-SAR-bisPSMA to participants at earlier stages of their disease, in the pre-chemotherapy setting, and to increase the number of participants in the Cohort Expansion Phase. Clarity expects to progress the SECuRE trial to a Phase III pivotal trial, with the potential combined market value of PSMA-targeted products estimated at approximately US$10-15 billion by 2030.

xReality Group Strengthens Balance Sheet and Focuses on Operator XR Growth

xReality Group (XRG) has entered into a debt repayment and subscription agreement with its largest shareholder, Birkdale Holdings, to convert $4.628 million in debt into equity at a 39% premium to the market price. This will strengthen XRG's balance sheet and support the company's growth strategy as it scales its Operator XR platform.

XRG's investor presentation highlighted the company's position as a market leader in immersive Extended Reality (XR) solutions, with Operator XR being the core growth asset. The company reported strong H1 FY25 results, with Operator XR revenue growing to $2.1 million, up $1.8 million on the prior comparative period. XRG expects Total Contract Value (TCV) for Operator XR to grow 80% year-over-year to $7.4 million by the end of FY25, with Annual Recurring Revenue (ARR) reaching $3.6 million.

Race Oncology Advances RC220 Bisantrene with $8.6 Million Phase 1 Trial Contract

Race Oncology has executed an $8.6 million contract with George Clinical International to support the clinical development of RC220 bisantrene, including a Phase 1 trial. The trial will evaluate the safety, tolerability, pharmacokinetics, and effects on biomarkers of RC220 in combination with doxorubicin. George Clinical, a leading global CRO, will conduct the trial across multiple sites in Australia, Hong Kong, and South Korea, using a Bayesian design for greater trial flexibility and speed.